Clinical Examination and Risk Classification of the Diabetic Foot

4

Lawrence A. Lavery and David G. Armstrong

Abstract

Foot ulceration is one of the most common precursors to lower extremity amputations among persons with diabetes (Singh et al., JAMA. 2005; 293(2):217–28; Boulton and Vileikyte, Wounds. 2000; 12(Suppl B):12B–8; Reiber et al., Rehabil Res Dev. 2001; 38(3):309–17). Ulcerations are pivotal events in limb loss for two important reasons. They allow an avenue for infection (Armstrong and Lipsky, Diabetes Technol Ther. 2004; 6:167–77), and they can cause progressive tissue necrosis and poor wound healing in the presence of critical ischemia. Infections involving the foot rarely develop in the absence of a wound in adults with diabetes, and ulcers are the most common type of wound in this population (Armstrong and Lipsky, Diabetes Technol Ther. 2004; 6:167–77). Foot ulcers, therefore, play a central role in the causal pathway to lower extremity amputation (Pecoraro et al., Diabetes Care. 1990; 13:513–21).

The etiology of ulcerations in persons with diabetes is commonly associated with the presence of peripheral neuropathy and repetitive trauma due to normal walking activities to areas of the foot exposed to moderate or high pressure and shear forces (Armstrong et al., J Foot Ankle Surg. 1998; 37(4):303–7). Foot deformities, limited joint mobility, partial foot amputations, and other structural deformities often predispose diabetics with peripheral neuropathy to abnormal weight bearing, areas of concentrated pressure, and abnormal shear forces that significantly increase their risk of ulceration (Cavanagh et al., Diabet Med. 1996; 13 Suppl

L.A. Lavery, DPM, MPH (✉)
Department of Plastic Surgery, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
e-mail: larry.lavery@utsouthwestern.edu

D.G. Armstrong, DPM, PhD
Department of Surgery,
University of Arizona and Southern Arizona Limb Salvage Alliance, Tucson, AZ, USA

A. Veves et al. (eds.), *The Diabetic Foot: Medical and Surgical Management*, Contemporary Diabetes,
DOI 10.1007/978-1-61779-791-0_4, © Springer Science+Business Media, LLC 2012

1:S17–22; Lavery et al., Diabetes Care. 1996; 19(8):818–21; Diabetes Care. 1995; 18(11):1460–2). Brand (The diabetic foot. In: Diabetes mellitus, theory and practice. Medical Examination) theorized that when these types of forces were applied to a discrete area over an extended period they would cause a local inflammatory response, focal tissue ischemia, tissue destruction, and ulceration. Clearly, identification of persons at risk for ulceration is of central importance in any plan for amputation prevention and diabetes care.

Keywords

Diabetic foot risk • Foot pathology • Sensory neuropathy • Tuning fork • Semmes–Weinstein monofilament • Vibration perception threshold • Modified neuropathy disability score • Limited joint mobility • Diabetic foot ulcer classification • Assessing a diabetic foot wound • Wagner ulcer classifications • UT ulcer classification

Foot ulceration is one of the most common precursors to lower extremity amputations among persons with diabetes [1–3]. Ulcerations are pivotal events in limb loss for two important reasons. They allow an avenue for infection [4], and they can cause progressive tissue necrosis and poor wound healing in the presence of critical ischemia. Infections involving the foot rarely develop in the absence of a wound in adults with diabetes, and ulcers are the most common type of wound in this population [4]. Foot ulcers, therefore, play a central role in the causal pathway to lower extremity amputation [5].

The etiology of ulcerations in persons with diabetes is commonly associated with the presence of peripheral neuropathy and repetitive trauma due to normal walking activities to areas of the foot exposed to moderate or high pressure and shear forces [6]. Foot deformities, limited joint mobility, partial foot amputations, and other structural deformities often predispose diabetics with peripheral neuropathy to abnormal weight bearing, areas of concentrated pressure, and abnormal shear forces that significantly increase their risk of ulceration [7–9]. Brand [10] theorized that when these types of forces were applied to a discrete area over an extended period they would cause a local inflammatory response, focal tissue ischemia, tissue destruction, and ulceration. Clearly, identification of persons at risk for ulceration is of central importance in any plan for amputation prevention and diabetes care.

In this chapter, we discuss the key risk factors to screen patients for foot complications. Risk factors may be broken down into four practical criterions to identify high-risk patients for ulceration and amputation. We subsequently discuss diabetic foot risk classification schemes and the two most commonly used classifications for diabetic foot ulcers.

Diabetic Foot Risk Classification

Preventing foot complications begins with identifying high-risk patients. Diabetic foot-screening programs are inexpensive and can be performed by technicians or nurses with very little training. The basics of screening involve identification of four main elements [11]: (1) history of lower extremity disease (foot ulceration, amputation, lower extremity bypass, or Charcot neuroarthropathy); (2) sensory neuropathy; (3) peripheral arterial disease; and (4) limited joint mobility or structural foot and ankle deformity.

A consensus document developed by the International Working Group on the Diabetic Foot (IWGDF) [12] is one of the most widely used systems (Table 4.1) to classify the diabetic foot. The risk of foot ulcers and amputations increased in each subsequent risk category

Table 4.1 International Working Group's diabetic foot risk classification

Risk Group 0	No neuropathy No peripheral arterial No foot deformity or limited joint mobility
Risk Group 1	Peripheral neuropathy No peripheral arterial No foot deformity or limited joint mobility
Risk Group 2	Peripheral neuropathy and foot deformity or limited joint mobility and/or Peripheral arterial disease
Risk Group 3	History of ulcer or amputation or Charcot

compared to baseline. Lavery et al. reported that a patient with neuropathy but no deformity or history of ulcer or amputation has a 1.7 times greater risk for ulceration compared with a patient without neuropathy [11]. Neuropathy with concomitant deformity or limited joint mobility yields a 12.1 times greater risk. Lastly, a patient with a history of previous ulceration or amputation has a 36.4 times greater risk for presenting with another ulcer. These risk factors compare to the first four categories in the classification system promoted by the IWGDF [13–15] (Table 4.1), and similar classification systems described by Rith-Najarian et al. [16] and Armstrong et al. [17]. Peters and Lavery [14] and Mayfield et al. [15] seem to corroborate this general line of assessment.

History of Foot Pathology

History of foot disease is the strongest predictor of ulceration and amputation. History is the least expensive screening measure [11, 18, 19]. It is the easiest risk group to identify, and the group most in need of frequent foot assessment, intensive education, therapeutic shoes, padded stockings, and rigorous blood glucose control. A current ulcer [19], past history of previous ulceration [19], or amputation [18] heightens the risk for further ulceration, infection, and subsequent amputation [5, 11, 20]. Patients in this risk group (Risk Category 3) are about 50 times more likely to have an ulcer in the next year and 36 times more likely to have an amputation compared to patients with no neuropathy or PAD (Risk Category 1) [21].



Fig. 4.1 Intrinsic muscular atrophy and foot deformity. Diabetic peripheral neuropathy also affects motor nerves, often causing atrophy of intrinsic musculature of the hand and foot. When this occurs, the extrinsic musculature work is unopposed, thus causing hammering of the toes and retrograde buckling of the metatarsal heads. Thus, both the toes (dorsally) and the metatarsal heads (plantarly) are more prominent and, therefore, more prone to neuropathic ulceration

There are several potential explanations for the increased risk. People with a history of ulceration or amputation have all the risk factors to reulcerate [12, 22]. Ulceration and amputation damage the integument and local biomechanics. After healing by secondary intention, the skin and soft tissue may be less resilient and less pliable, so they are more prone to injury. In addition, persons with a partial foot amputation often develop local foot deformities secondary to biomechanical imbalances that may cause further foci of pressure [23–25]. Structural deformities increase pressures on the sole of the foot and are associated with ulceration (Fig. 4.1). A classic example is clawing of the lesser toes and subluxation and dislocation of the metatarsophalangeal joints [25].

Sensory Neuropathy

Neuropathy is a major component of nearly all diabetic ulcerations [26]. Loss of protective sensation is a term that is often used to describe a

level of sensory loss that allows patients to jury themselves without recognizing the injury. These patients are vulnerable to physical and thermal trauma that increases the risk of foot ulceration twofold [21]. Patients with neuropathy often wear a hole in their foot much as sensate patients might wear a hole in their stocking or shoe.

Screening for neuropathy is noninvasive, fast, and inexpensive. Several consensus documents recommend that all patients with diabetes should be screened annually for sensory neuropathy [1, 27]. There are several techniques to screen for neuropathy. The absence of protective sensation may be determined using a tuning fork, a Semmes–Weinstein 10-g monofilament (SWM) nylon wire, a calibrated vibration perception threshold (VPT) meter, or a comprehensive physical examination [19].

Inspection of the feet may provide valuable clues as to the presence and severity of sensory neuropathy. Atrophy of the intrinsic muscles of the hands and feet is often a late-stage condition that is very frequently associated with polyneuropathy. When this occurs, the extrinsic muscles of the foot are unopposed, thus causing hammering of the toes and retrograde buckling of the metatarsal heads. Thus, both the toes (dorsally) and the metatarsal heads (plantarly) are more prominent and, therefore, more prone to neuropathic ulceration. This condition often leads to prominent digits and metatarsal heads, and (in the face of sensory loss) has been associated with increased risk for neuropathic ulceration. Similarly, bleeding into callus is a not an uncommon condition which is associated with neuropathy. Patients with autonomic neuropathy may present with dry skin that is poorly hydrated.

Tuning Fork

The conventional 128-Hz tuning fork is an easy and inexpensive tool to assess vibratory sensation. The test is considered positive when patients lose vibratory sensation while the examiner still perceives it [1]. The tuning fork is struck until it clangs, and the tip of the tuning fork is held against a bony prominence, such as the distal tip of the great toe. Patients are asked if they can feel the vibration. If they feel pressure but no vibration, they have loss of vibration sensation. In addition, patients should be able to feel the vibration for about 20 s. If they cannot feel the vibration for 20 s, they have abnormal vibration sensation. In addition to a standard 128-Hz tuning fork, a graduated tuning (Rydel-Seiffer) fork has provided comparable results to the vibration perception testing (r, –0.90; $P < .001$) [28, 29]. Using the graduated tuning fork, patients indicate first loss of vibration at the plantar hallux as the intersection of two virtual triangles moves on a scale exponentially from 0 to 8 in a mean (AD) of 39.8 (1) seconds [30].

Semmes–Weinstein Monofilament

The SWM is one of the most frequently utilized screening tools in the USA for identifying loss of protective sensation [1, 31]. The inability to perceive the 10-g SWM has been associated with large-fiber neuropathy [32, 33]. In three prospective studies, the 5.07 or 10-g SWM identified persons at increased risk of foot ulceration with a sensitivity of 65–91%, a specificity of 36–86%, a positive predictive value of 18–39%, and a negative predictive value of 90–95% [18, 34, 35] (Table 4.2). The SWM consists of a plastic handle supporting a nylon filament. It is portable, inexpensive, easy to use, and provides excellent negative predictive ability for the risk of ulceration and amputation [36].

There are a number of important concerns regarding the SWM. There is a wide variability in the accuracy and durability of SWM sold in the USA. Certain brands of monofilaments are more accurate than others [37]. Instruments made in the UK seem to have better initial accuracy and calibration [36]. SWMs experience material failure of the nylon monofilament and become less accurate with repeated measurements. Therefore, it is important to purchase calibrated instruments and replace them on a regular basis. In a clinical setting, it is best for the evaluator to have more than one monofilament available, as after numerous uses without a chance to "recover," the monofilament may buckle at a reduced amount of pressure, thus making it oversensitive and therefore less accurate [37].

Table 4.2 10-g Monofilament to diagnose sensory neuropathy

Study	Prevalence of ulcers (%)	Sensitivity	Specificity	Positive predictive value	Negative predictive value
Rith-Najarian [34]	11	65	86	39	95
Rith-Najarian (2000)	29	91	36	34	90
Boyko (1999)	11	68	62	18	94

Table 4.3 Results of monofilament testing with different pressure thresholds

Study	Prevalence of ulcers (%)	Sensitivity (%) Specificity (%) Positive (%)	Positive predictive value
Mueller (1989)	30	100 100	No ulcer patients felt 5.07 monofilament
Birke (1986)	100		No ulcer patients felt 6.10 monofilament
Sosenko (1990)	29	84 96 76	76%, 4.21 monofilament

Longevity and recovery testing results from an independent study suggest that each monofilament, regardless of the brand, will survive usage on approximately ten patients before needing a recovery time of 24 h before further use [31, 37]. Furthermore, differences in materials used in manufacture and environmental factors may also change the characteristics of the monofilament [37, 38].

It is clear that monofilaments should be replaced every few months to get reliable results. For instance, Booth and colleagues evaluated four brands on 10-g monofilaments. They reported that after 100 loading cycles "most" monofilaments were within 10% of the 10-g loading force. However, after 200 cycles, only 50% met that criteria.

Testing with the SWM is performed with the patient sitting supine in the examination chair with both feet level. The monofilament is applied perpendicular to the skin until it bends or buckles from the pressure. It should be left in place for approximately 1 s and then released [1]. The monofilament should be demonstrated on the patient's hand so that he/she can understand the level of pressure provided during testing. The patient should close his/her eyes for the foot examination. They should be instructed to say "yes" each time they feel the monofilament and then to identify the site where they felt the monofilament. The number of sites that should be tested with monofilaments is unclear. However, because testing is noninvasive and inexpensive, the number of sites should not be a limiting factor in testing protocols. Some authorities have recommended that measurements be taken at each of the ten sites on the foot [39]. These include the first, third, and fifth digits plantarly, the first, third, and fifth metatarsal heads plantarly, the plantar midfoot medially and laterally, the plantar heel, and the distal first interspace dorsally. However, testing just four plantar sites on the forefoot (the great toe, and base of the first, third, and fifth metatarsals) identifies 90% of patients with loss of protective sensation [40].

By convention, the 5.07 or 10-g monofilament has been commonly associated with neuropathy with loss of protective sensation. However, there are many grades of monofilaments that are available, and both lower and higher forces have been evaluated and associated with "loss of protective sensation." For instance, Sonseko and colleagues evaluated a 4.21 monofilament and found good sensitivity, specificity, and positive predictive value. Birke and colleagues evaluated the 6.10 or 60-g monofilament and found that none of the patients they evaluated could feel the monofilament (Table 4.3).

Vibration Perception Threshold Testing

A VPT meter is a semiquantitative tool to assess large-fiber neuropathy. The VPT meter (also known as biothesiometer or neurothesiometer) is a handheld device with a rubber tactor that vibrates at 100 Hz. The handheld unit is connected by an electrical cord to a base unit. This unit contains a linear scale which displays the applied voltage, ranging from 0 to 100 V (converted from microns [35, 41] (Fig. 4.2). The device is held with the tactor balanced vertically on the pulp of the toe. The voltage amplitude is then increased on the base unit until the patient can perceive a vibration. A mean of three readings (measured in Volts) is generally used to determine the VPT for each foot. "Loss of protective sensation" with VPT has commonly been considered to be about 25 V. The level of VPT testing can help to predict ulceration. In a prospective cohort study, Abbott and colleagues evaluated 1,035 patients with diabetes, no history of a foot ulcer, and a VPT greater than 25. During the follow-up period, the yearly ulcer incidence was 7.2%. For every 1 V increase in VPT, there was a 5.6% increase in the risk of foot ulceration [42].



Fig. 4.2 Vibration perception threshold (VPT) meter. The vibrating tactor is placed at the distal pulp of the great toe. The amplitude (measured in volts) is increased on the base unit until the patient feels a vibration. This is termed VPT. A VPT greater than 25 V may be an optimal combination of sensitivity and specificity for identifying clinically significant loss of protective sensation using this device

VPT testing has been shown to have very good sensitivity and specificity (Table 4.4). In a prospective 4-year study, a VPT of more than 25 V had a sensitivity of 83%, a specificity of 63%, a positive likelihood ratio of 2.2, and a negative likelihood ratio of 0.27 for predicting foot ulceration [43, 44].

Modified Neuropathy Disability Score

Clinical assessment can be used to score the severity of peripheral neuropathy in order to identify high-risk patients. The Modified Neuropathy Disability Score (NDS) is a clinical assessment scoring scheme that uses standard clinical tools. These include deep tendon reflexes of Achilles tendons, vibration sensation with 128-Hz tuning fork, pinprick, and hot and cold rods. Use of these instruments, combined into a disability score, has proven to be predictive of future diabetic foot complications [19]. In a population-based prospective study, Abbot evaluated 9,710 patients with diabetes from 6 health

Table 4.4 Vibration perception threshold testing

	Prevalence of ulcers (%)	Sensitivity (%)	Specificity (%)	Positive predictive value
Sosenko (1990)	29	83	87	49%
Vileikyte (1997)	28	86	79	NS
Armstrong (1998)	33	80	85	NS

NS not stated

districts in the UK. During the 2-year follow-up period, there were 291 ulcers. Only 1.1% of patients with an NDS less than 6 developed a foot ulcer, and 6.3% of patients with NDS greater than 6 developed an ulcer [19].

Limited Joint Mobility

Neuropathy and foot deformity, when combined with repetitive or constant stress, can lead to ulceration. Characteristically, the highest plantar pressure is associated with the site of ulceration [6, 7, 45–47]. In one study of patients with peripheral neuropathy, 28% with high plantar pressure developed a foot ulcer during a 2.5-year follow-up compared with none with normal pressure [48].

Clinicians should examine the feet for structural abnormalities, including hammer or claw toes, flat feet, bunions and calluses, and reduced joint mobility to help identify pressure points that are susceptible to future ulceration. Structural deformity is frequently accompanied by limited joint mobility. Nonenzymatic glycosylation of periarticular soft tissues or tendons may contribute to limited joint motion in the person with diabetes. Neuropathy can lead to atrophy of the intrinsic muscles of the hands and feet which can cause instability at the metatarsophalangeal joint and digits [49–51]. Limitation of motion reduces the foot's ability to accommodate for ground reactive force and, therefore, increases plantar pressures [9, 52–55]. Limitation of motion of the first metatrsaophalangela joint has been defined as less than 50° of passive dorsiflexion of the hallux [11, 56] (Fig. 4.3). Additionally, glycosylation may deleteriously affect the resiliency of the Achilles tendon, thereby pulling the foot into equinus and further increasing the risk for both ulceration and Charcot arthropathy (Fig. 4.4).



Fig. 4.3 Evaluation of first metatarsophalangeal joint dorsiflexion (limited joint mobility). Limited joint mobility is frequently encountered in patients with long-standing diabetes. This is most significant in the ankle joint (equinus) and the forefoot. Less than 50° of dorsiflexion at the first metatarsal phalangeal joint indicates clinically significant limited joint mobility



Fig. 4.4 Equinus and its relationship to elevated forefoot plantar pressure. Shortening or loss of natural extensibility of the Achilles tendon may lead to pulling of the foot into plantarflexion. This leads to increased forefoot pressure (increasing risk for plantar ulceration) and, in some patients, may be a component of midfoot collapse and Charcot arthropathy

Diabetic Foot Ulcer Classification

Foot ulcer in persons with diabetes is one of the most common precursors to lower extremity amputation. Appropriate care of the diabetic foot ulceration requires a clear, descriptive

classification system that can be used to direct therapy, communicate risk, and possibly predict outcome. Speaking a "common language" when communicating risk in the diabetic foot is, therefore, essential. This tenet is most important when treating acute diabetic sequelae, such as the diabetic wound. A classification system, if it is to be clinically useful, should be easy to use, reproducible, and effective to accurately communicate the status of wounds in persons with diabetes mellitus. There are a variety of variables that could be included in such a system, such as faulty wound healing, compliance issues, quality of wound granulation tissue, host immunity, nutritional status, and comorbidities. However, most of these variables are difficult to measure or categorize and can complicate a system, so it is not useful as a clinical tool. In contrast, three well-documented, relatively quantifiable factors associated with poor wound healing and amputation include depth of the wound [57, 58], presence of infection, and presence of ischemia [15, 59].

Seven Essential Questions to Ask When Assessing a Diabetic Foot Wound

A classification system has little value if the clinician employing it does not approach each wound in a stepwise, consistent, and logical fashion. When employing this approach, the first four questions are useful in terms of their descriptive value. The last three questions are most useful for their predictive qualities.

1. Where is the ulcer located?
   Location of a wound and its etiology go hand in hand. Generally, wounds on the medial aspect of the foot are caused by constant low pressure (e.g., tight shoes), whereas wounds on the plantar aspect of the foot are caused by repetitive moderate pressure (e.g., repetitive stress on prominent metatarsal heads during ambulation).
2. How large is the ulcer?
   Size of the wound plays a key role in determining duration to wound healing. To simplify wound diameter measurements, one may trace the wound on sterile acetate sheeting and tape this tracing into the chart (Fig. 4.5). The tracing can also be performed on the outer wrapping of an instrument sterilization pack (which would otherwise be discarded). Recently, many centers have begun employing digital photography and computer-driven planimetric wound area calculations. This provides for potentially more consistent, accurate measurements and, ultimately, for comparison of wound healing rates with other centers regionally and beyond. In an evaluation of the reproducibility of wound measurement techniques, Wunderlich and coworkers reported that wound tracing and digital planimetric assessment were by far more reliable than manual measurement of length and width [60].
3. What does the base look like?
   When describing the base of a wound, one may use terms like granular, fibrotic, or necrotic. One may record the presence or absence of any drainage, which may be described as serous or purulent, with a further description of any odor or color, as necessary.
4. What do the margins look like?
   The margins tell us a lot about the wound. If adequately debrided and off-loaded, they should be well adhered to the surface of the underlying subcuticular structures with a gentle slope toward normal epithelium. However, in the inadequately debrided, inadequately off-loaded wound, undermining of the leading edge normally predominates. This is due to the "edge effect" which dictates that an



Fig. 4.5 Tracing the wound using sterile acetate sheet. Wound tracing may yield far more reproducible results in measuring wound size than simply length by width measurement

interruption in any matrix (in this case, skin) magnifies both vertical and shear stress on the edges of that interruption. This subsequently causes shearing from the underlying epithelium (making the wound larger by undermining) and increased vertical pressure (making the wound progressively deeper). If appropriately debrided and off-loaded, this effect will be mitigated. Nonetheless, the margins of the wound should be classified as undermining, adherent, macerated, and/or nonviable.

Subsequent to the first questions, which we term "descriptive," come the last three questions, which we term "classifiers." These classifiers can then be used to fit a patient into the University of Texas wound classification system. This system has evolved as a significant modification of the Wagner system to include concomitant depth, infection, and ischemia. While both systems have been shown to be predictive of poor outcomes, the UT system has been shown to be significantly more predictive and complete [61, 62]. Both, however, may be considered useful in a clinical scenario, depending on the preference of the clinician.

5. How deep is the ulceration? Are there underlying structures involved?
   These two questions are so closely related that they are combined into one. There is a possible contribution of depth to ulcer healing times [63]. Depth of the wound is the most commonly utilized descriptor in wound classification. Wounds are graded by depth. Grade 0 represents a pre- or postulcerative site. Grade 1 ulcers are superficial wounds through the epidermis or epidermis and dermis but do not penetrate to tendon, capsule, or bone. Grade 2 wounds penetrate to tendon or capsule. Grade 3 wounds penetrate to bone or into a joint. We have known for some time that wounds that penetrate to bone are frequently osteomyelitic [57]. Additionally, we have observed that morbid outcomes are intimately associated with progressive wound depth.

   Depth of the wound and involvement of underlying structures may best be appreciated through the use of a sterile blunt metallic probe. The instrument is gently inserted into the wound and the dimensions of the wound may be explored. Additionally, bony involvement is typically readily appreciable through this method.
6. Is there infection?
   The definition of bone and soft tissue infection is not an easy one. Cultures, laboratory values, and subjective symptoms are all helpful. However, the diagnosis of an infection's genesis and resolution has been and continues to be a clinical one. While criteria for infection may be something less than clear-cut, there is little question that the presence of infection is a prime cause of lower extremity morbidity and frequently eventuates into wet gangrene and subsequent amputation. Therefore, in an effort to facilitate communication and effect consistent results, the foot care team should agree on the criteria for this very important risk factor.
7. Is there ischemia?
   As discussed above, identification of ischemia is of utmost importance when evaluating a wound. Ischemic wounds were found to take longer to heal compared to neuropathic wounds without deformities [63]. If pulses are not palpable or if a wound is sluggish to heal even in the face of appropriate off-loading and local wound care, noninvasive vascular studies are warranted followed by a prompt vascular surgery consultation and possible intervention to improve perfusion.

Wagner Ulcer Classifications

Several diabetic classification systems have been reported in the medical literature. This section aims to chronologically review some of the most commonly described classification systems currently used by a variety of practitioners to stage diabetic foot wounds and to discuss outcomes related to their use. One of the most frequently cited diabetic wound classification systems was first described by Meggitt [64] in 1976 and Wagner [65] in 1981. The system is based mainly on wound depth and consists of six wound grades. These include Grade 0 (intact skin), Grade 1 ("superficial ulcer"), Grade 2 (deep ulcer to tendon, bone, or joint), Grade 3 (deep ulcer with abscess or osteomyelitis), Grade 4 ("forefoot



Fig. 4.6 Meggitt–Wagner wound classification system

gangrene"), and Grade 5 ("whole-foot gangrene"). This classification is outlined in Fig. 4.6.

The classification system contains three key descriptors, including depth, infection, and ischemia. However, it does not consistently include these important risk factors in every ulcer grade. Infection is included in only one of the six Wagner ulcer grades, and vascular disease is only included in the last two classification grades. The first three grades are concerned only with depth. It is perhaps for this reason that they are the most commonly used, whereas the last three are largely ignored because of their limited clinical use. The descriptors Meggit and Wagner used for ischemia were forefoot and whole-foot gangrene. These represent the most severe form of end-stage disease, and therefore cannot help to guide proactive interventional therapy, except frank ablation of the affected site. In addition, because gangrene can be caused by infection, it may not always have a vascular origin. Since there are better diagnostic tools to assess and treat PAD, more robust criteria for ischemia will improve diagnosis, interventions, and amputation prevention.

There are several papers that have attempted to validate the Wagner classification system [66, 67]. Calhoun et al. [67] evaluated wounds that were infected and retrospectively assigned Wagner grades to them. They found that when wounds were treated according to what they considered a healthy standard of care, then success, which they defined as eradication of infection and prevention of readmission for 1 year, was frequently achieved despite wound grade [67]. Van Acker [68] found the Wagner classification to have significant association with the duration of healing of the ulcer. Armstrong et al. [62] suggested that patients with Wagner stages 4 and 5 may be grouped together as the two groups did not have separate prognostic value. In addition, these patients are often referred directly to a surgeon for amputation and are rarely seen by the diabetic foot team. The system was adapted to combine medical and surgical elements of therapy to monitor the treatment of diabetic foot infection. Unfortunately, in requiring that wounds be infected as an inclusion criterion, it made assessment of this classification problematic, as Wagner wound grades 0–2 classically have no infection descriptor attached to them. In fact, the only mention of infection in this system occurs in Grade 3. It is this fact that causes many to customize this system such that it often takes on distinctly different regional characteristics. This unfortunately limits its usefulness as a standard diabetic foot classification.

In the 1980s and 1990s, many authors, including Forrest and Gamborg-Nelson [69], Pecoraro and Reiber [70], Arlt and Protze [71], and Knighton et al. [72], proposed their own wound classifications; however, these systems have not gained universal acceptance. More recent classification systems that have been proposed include the UT classification modification by Armstrong and Peters [63], the PEDIS system by IWGDF members [73], and the S(AD) SAD system proposed by Macfarlane and Jeffcoate [74, 75]. These systems will require validation and to gain universal acceptance.

UT Ulcer Classification

The University of Texas Health Science Center in San Antonio (UT) proposed a classification that included depth, infection, and vascular status in 1996 [62, 76]. The classification integrates a system of wound grade and stage to categorize wounds by severity. It is based around two fundamental questions the clinician asks when assessing a wound: (1) How deep is the wound? and (2) Is the wound infected, ischemic, or both? The classification formulates into a matrix with infection and/or ischemia as the vertical axis and depth as the longitudinal axis. This system is illustrated in Fig. 4.7.

Scale	Grade 0	Grade 1	Grade 2	Grade 3
A	Pre or postulcerative lesion completely epithelialized	Superficial wound, not involving tendon, capsule, or bone	Wound penetrating to tendon or capsule	Wound penetrating to bone or joint
B	with infection	with infection	with infection	with infection
C	with ischemia	with ischemia	with ischemia	with ischemia
D	with infection and ischemia	with infection and ischemia	with infection and ischemia	with infection and ischemia

Fig. 4.7 University of Texas wound classification system

Similar to other wound classification systems, the UT system grades wounds by depth. Grade 0 represents a pre- or postulcerative site. Grade 1 ulcers are superficial wounds through either the epidermis or the epidermis and dermis but do not penetrate to tendon, capsule, or bone. Grade 2 wounds penetrate to tendon or capsule, but the bone and joints are not involved. Grade 3 wounds penetrate to bone or into a joint. Within each wound grade, there are four stages: clean wounds (A), nonischemic infected wounds (B), ischemic wounds (C), and infected ischemic wounds (D).

The Grade 0 wound: Grade 0 wounds are preulcerative areas or previous ulcer sites that are now completely epithelialized after debridement of hyperkeratosis and nonviable tissue. The diagnosis of a Grade 0 wound can be made only after removal of any regional hyperkeratosis, as quite often frank ulcerations may be hidden by overlying calluses. The Grade 0-A wound is then a preulcerative area or a completely epithelialized postulcerative are. The Grade 0-B wound is a 0-A lesion with associated cellulitis. The Grade 0-C wound is a 0-A lesion with concomitant regional signs of ischemia. The Grade 0-D wound is a 0-B lesion coupled with a working diagnosis of lower extremity ischemia as defined above.

Although lesions that fall into the Grade 0 category do not have a break in the epidermis and may not be classically classified as "wounds," the category is important in the identification of sites that are "at risk" for future ulceration and to monitor and prevent reulceration of newly healed wounds. Because there is a very high rate of reulceration (28–50%) [12], the Grade 0 classification allows physicians to follow the progression of wounds over time from healed to reulcerated.

The Grade I wound: Grade I wounds are superficial in nature. They may be either partial or full-thickness skin wounds without the involvement of tendon, capsule, or bone. The Grade I-A wound is, therefore, superficial, partial, or full-thickness wound. The Grade I-B wound is an infected superficial wound. As with any neuropathic lesion, Grade I-B wounds should be examined very carefully. By definition, the Grade I-B wound implies superficial infection without the involvement of underlying structures. If the wound shows signs of significant purulence or fluctuance, further exploration to expose a higher grade infection is in order. The Grade I-C wound is I-A plus vascular compromise and the Grade I-D wound is the infected I-B wound with concomitant ischemia.

The Grade II wound: Grade II wounds probe deeper than the Grade I wounds. Grade II wounds may involve tendon or joint capsule but not bone. The reason for the distinct delineation between wounds that probe to bone and those without bone or joint involvement is because of the high correlation between probing to bone and osteomyelitis (Lavery, 2005 #11205) [57, 77].

The II-A wound may, therefore, probe to tendon or joint capsule, but not bone. The II-B wound is II-A plus infection, and again the bone and joint are not involved. The Grade II-C wound is II-A plus ischemia, and the Grade II-D wound corresponds to II-B plus ischemia.

The Grade III wound: A wound that probes to bone is categorized as a grade III wound. The modifiers are then added pending the presence of comorbid factor. The III-A wound probes to bone without local or systemic signs of acute infection. The III-B wound probes to bone with signs of acute infection. The III-C wound is identical to III-A with concomitant ischemia. The III-D wound is characterized by active infection, exposed bone, and vascular insufficiency.

The criterion for each of the stages is based on clinical and laboratory data. The working diagnosis of lower extremity ischemia may be based on clinical signs and symptoms, such as absence of pedal hair, absent pulses, claudication, rest pain, atrophic integument, dependent rubor or pallor on elevation, plus one or more of the noninvasive criteria (transcutaneous oxygen measurements of <40 mmHg, ankle-brachial index of <0.80, or absolute toe systolic pressure <45 mmHg) [78–82].

Clean ulcers may be defined as wounds without local or systemic signs of infection. The clinical diagnosis of infection in persons with diabetes is often difficult and defined by narrow, subtle parameters. Wounds with frank purulence and/or two or more of the following local signs may be classified as "infected": warmth, erythema, lymphangitis, lymphadenopathy, edema, pain, and loss of function. Systemic signs of infection may include fever, chills, nausea, vomiting, or generalized malaise [83]. This clinical diagnosis of infection is often obscured by neuropathy and possibly immunopathy. In the insensitive foot, pain and/or loss of function are poor indicators of inflammation and infection [84]. Likewise, diabetic subjects have been shown to posses deficiencies in leukocyte adherence, chemotaxis, phagocytosis, and diapedesis [85–87] and often do not have leukocytosis in the presence of acute soft tissue or bone infection [84, 88, 89]. Warmth and edema are less than ideal indicators of infection, as ulcerated sites tend to be warmer and more edematous than the corresponding site contralaterally regardless of the presence of infectious disease [90]. However, despite these impediments, diagnosis of a diabetic foot infection remains primarily a clinical one [88, 89]. The diagnosis and subsequent treatment of infection may also be assisted by laboratory studies, positive deep tissue cultures, or wound-based curettage [91]. When osteomyelitis is suspected, bone biopsy with appropriate pathology and culture studies is still the gold standard for diagnosis.

Armstrong et al. validated the predictive value of the UT classification system in 1998 [62] and noted a significant overall trend toward an increased prevalence of amputations as wounds increased in both grade (depth) and stage (comorbidity). For example, patients whose wounds were both infected and ischemic were noted to be almost 90 times more likely to receive a high-level amputation compared with patients in a less advanced wound stage, and patients whose wound probed to the underlying bone were over 11 times as likely to receive a high-level amputation [63]. Unfortunately, the study was retrospective and was not a multicenter trial. In addition, some degree of bias may have been present since the study was carried out by the center that first described the system and the clinicians using it that are intimately familiar with the system.

Oyibo et al. [92] compared the Wagner classification system with the UT system in a multicenter, prospective, longitudinal, case–control study of 194 patients. The study suggested that both the UT and the Wagner classification system correlated similarly with clinical outcome. Both systems associated higher grades with a greater likelihood of an ulcer not healing and a greater chance of limb amputation [63]. The trend for grade of the UT classification system was slightly more robust than the trend for grade of the Wagner classification. The inclusion of comorbid factors, such as infection and/or ischemia, to grade (depth) when classifying an ulcer with the UT system improves description and adds to the predictive power of a wound classification system, especially for ulcers within the same grade level but at a different stage. Based on this, the UT

wound classification showed promise as a more practical system.

As with other classification systems, the UT classification is not void of potential shortcomings. Neuropathy, considered by many to be an important etiologic and prognostic factor, is not included in the UT classification system. This exclusion is based on the argument that neuropathy is a preexisting condition in most diabetic foot wounds and it is not a significant independent risk factor. The UT classification system also does not describe the anatomic region of the wound: however, it is still not clear that anatomic is a factor that would either change treatment or clinical outcomes. Another shortcoming of the UT classification system is that it leaves no room for more specificity or complexity. Simplicity is one reason that the Wagner classification has remained popular. The UT classification is already fairly complex with four-by-four matrix-grading system. Additional information that is not strongly associated with triggering a change in treatment could hinder the practical application of wound classification.

All the proposed classification systems have attempted to integrate local factors with varying degrees of validated success. These systems might be viewed with the same considerations we use when we think of a language. A universal idiom has dialects, accents, and pragmatic slang. Different exposure and usage of the language will cause it to change over time. These dialects should be judged in light of a progress toward a lower global prevalence of lower extremity amputations. To avoid inconsistencies, we need to move toward a validated and universally accepted diabetic foot wound classification system.

In conclusion, it is observed that many of the most common component causes for neuropathic ulceration, infection, and subsequent amputation may be identified using simple, inexpensive equipment in a primary care setting. A consistent, thoughtful assessment of the diabetic foot is pivotal to identify high-risk patients. Subsequent to the gathering of clinical data through sequential assessment, appropriate classification of the wound becomes paramount in our efforts to document and communicate the level of risk to all members of the health care team caring for the person with diabetes. These simple approaches should improve communication and facilitate amputation prevention.

References

1. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293(2): 217–28.
2. Boulton AJM, Vileikyte L. Pathogenesis of diabetic foot ulceration and measurements of neuropathy. Wounds. 2000;12(Suppl B):12B–8.
3. Reiber GE, Smith DG, Carter J, et al. A comparison of diabetic foot ulcer patients managed in VHA and non-VHA settings. J Rehabil Res Dev. 2001;38(3): 309–17.
4. Armstrong DG, Lipsky BA. Advances in the treatment of diabetic foot infections. Diabetes Technol Ther. 2004;6:167–77.
5. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation: basis for prevention. Diabetes Care. 1990;13:513–21.
6. Armstrong DG, Peters EJ, Athanasiou KA, Lavery LA. Is there a critical level of plantar foot pressure to identify patients at risk for neuropathic foot ulceration? J Foot Ankle Surg. 1998;37(4):303–7.
7. Cavanagh PR, Ulbrecht JS, Caputo GM. Biomechanical aspects of diabetic foot disease: aetiology, treatment, and prevention. Diabet Med. 1996;13 Suppl 1: S17–22.
8. Lavery LA, Vela SA, Lavery DC, Quebedeaux TL. Reducing dynamic foot pressures in high-risk diabetic subjects with foot ulcerations. A comparison of treatments. Diabetes Care. 1996;19(8):818–21.
9. Lavery LA, Lavery DC, Quebedeax-Farnham TL. Increased foot pressures after great toe amputation in diabetes. Diabetes Care. 1995;18(11):1460–2.
10. Brand PW. The diabetic foot. In: Ellenberg M, Rifkin H, editors. Diabetes mellitus, theory and practice. 3rd ed. New York: Medical Examination; 1983. p. 803–28.
11. Lavery LA, Armstrong DG, Vela SA, Quebedeaux TL, Fleischli JG. Practical criteria for screening patients at high risk for diabetic foot ulceration. Arch Intern Med. 1998;158:158–62.
12. Uccioli L, Faglia E, Monticone G, et al. Manufactured shoes in the prevention of diabetic foot ulcers. Diabetes Care. 1995;18(10):1376–8.
13. International working group on the diabetic foot. International Consensus on the Diabetic Foot. Maastricht: International Working Group on the Diabetic Foot; 1999.
14. Peters EJ, Lavery LA. Effectiveness of the diabetic foot risk classification system of the International Working Group on the Diabetic Foot. Diabetes Care. 2001;24(8):1442–7.

15. Mayfield JA, Reiber GE, Nelson RG, Greene T. A foot risk classification system to predict diabetic amputation in Pima Indians. Diabetes Care. 1996; 19(7):704–9.
16. Rith-Najarian S, Branchaud C, Beaulieu O, Gohdes D, Simonson G, Mazze R. Reducing lower-extremity amputations due to diabetes. Application of the staged diabetes management approach in a primary care setting. J Fam Pract. 1998;47(2):127–32.
17. Armstrong DG, Lavery LA, Harkless LB. Who's at risk for diabetic foot ulceration? Clin Podiatr Med Surg. 1998;15:11–9.
18. Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Davignon DR, Smith DG. A prospective study of risk factors for diabetic foot ulcer. The Seattle Diabetic Foot Study. Diabetes Care. 1999;22(7):1036–42.
19. Abbott CA, Carrington AL, Ashe H, et al. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med. 2002;19(5): 377–84.
20. Goldner MG. The fate of the second leg in the diabetic amputee. Diabetes. 1960;9:100–3.
21. Lavery LA, Peters EJ, Williams JR, Murdoch DP, Hudson A, Lavery DC. Reevaluating the way we classify the diabetic foot: restructuring the diabetic foot risk classification system of the International Working Group on the Diabetic Foot. Diabetes Care. 2008; 31(1):154–6.
22. Helm PA, Walker SC, Pulliam GF. Recurrence of neuropathic ulcerations following healing in a total contact cast. Arch Phys Med Rehabil. 1991;72(12): 967–70.
23. Armstrong DG, Lavery LA, Vela SA, Quebedeaux TL, Fleischli JG. Choosing a practical screening instrument to identify patients at risk for diabetic foot ulceration. Arch Intern Med. 1998;158:289–92.
24. Quebedeaux TL, Lavery LA, Lavery DC. The development of foot deformities and ulcers after great toe amputation in diabetes. Diabetes Care. 1996;19(2): 165–7.
25. Murdoch DP, Armstrong DG, Dacus JB, Laughlin TJ, Morgan CB, Lavery LA. The natural history of great toe amputations. J Foot Ankle Surg. 1997;36(3): 204–8.
26. Reiber GE, Vileikyte L, Boyko EJ, et al. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care. 1999;22(1):157–62.
27. Olaleye D, Perkins BA, Bril V. Evaluation of three screening tests and a risk assessment model for diagnosing peripheral neuropathy in the diabetes clinic. Diabetes Res Clin Pract. 2001;54(2):115–28.
28. Liniger C, Albeanu A, Bloise D, Assal JP. The tuning fork revisited. Diabet Med. 1990;7(10):859–64.
29. Kastenbauer T, Sauseng S, Brath H, Abrahamian H, Irsigler K. The value of the Rydel-Seiffer tuning fork as a predictor of diabetic polyneuropathy compared with a neurothesiometer. Diabet Med. 2004; 21(6):563–7.
30. Thivolet C, el Farkh J, Petiot A, Simonet C, Tourniaire J. Measuring vibration sensations with graduated tuning fork. Simple and reliable means to detect diabetic patients at risk of neuropathic foot ulceration. Diabetes Care. 1990;13(10):1077–80.
31. Armstrong DG. The 10-g monofilament: the diagnostic divining rod for the diabetic foot? Diabetes Care. 2000;23(7):887 [Editorial].
32. Sorman E, Edwall LL. [Examination of peripheral sensibility. Vibration test is more sensitive than monofilament test]. Lakartidningen. 2002;99(12):1339–40.
33. Gin H, Rigalleau V, Baillet L, Rabemanantsoa C. Comparison between monofilament, tuning fork and vibration perception tests for screening patients at risk of foot complication. Diabetes Metab. 2002;28(6 Pt 1):457–61.
34. Rith-Najarian SJ, Stolusky T, Gohdes DM. Identifying diabetic patients at risk for lower extremity amputation in a primary health care setting. Diabetes Care. 1992;15(10):1386–9.
35. Pham HT, Armstrong DG, Harvey C, Harkless LB, Giurini JM, Veves A. Screening techniques to identify the at risk patients for developing diabetic foot ulcers in a prospective multicenter trial. Diabetes Care. 2000;23:606–11.
36. Yong R, Karas TJ, Smith KD, Petrov O. The durability of the Semmes-Weinstein 5.07 monofilament. J Foot Ankle Surg. 2000;39(1):34–8.
37. Booth J, Young MJ. Differences in the performance of commercially available 10-g monofilaments. Diabetes Care. 2000;23(7):984–8.
38. Ulbrecht JS, Cavanagh PR, Caputo GM. Foot problems in diabetes: an overview. Clin Infect Dis. 2004;39 Suppl 2:S73–82.
39. Mueller MJ. Identifying patients with diabetes who are at risk for lower extremity complications: use of Semmes-Weinstein monofilaments. Phys Ther. 1996; 76(1):68–71.
40. Smieja M. Clinical examination for the detection of protective sensation in the feet of diabetic patients. International Cooperative Group for Clinical Examination Research. J Gen Intern Med. 1999;14(7): 418–24.
41. Armstrong DG. Loss of protective sensation: a practical evidence-based definition. J Foot Ankle Surg. 1999;38(1):79–80.
42. Abbott CA, Vileikyte L, Williamson S, Carrington AL, Boulton AJ. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care. 1998;21(7):1071–5.
43. Mason J, O'Keeffe C, Hutchinson A, McIntosh A, Young R, Booth A. A systematic review of foot ulcer in patients with Type 2 diabetes mellitus. II: treatment. Diabet Med. 1999;16(11):889–909.
44. Young MJ, Breddy JL, Veves A, Boulton AJ. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study. Diabetes Care. 1994;17(6):557–60.
45. Boulton AJM. The importance of abnormal foot pressure and gait in causation of foot ulcers. In: Connor H,

Boulton AJM, Ward JD, editors. The foot in diabetes. 1st ed. Chilchester: Wiley; 1987. p. 11–26.
46. Duckworth T, Betts RP, Franks CI, Burke J. The measurement of pressure under the foot. Foot Ankle. 1982;3:130.
47. Birke JA, Novick A, Graham SL, Coleman WC, Brasseaux DM. Methods of treating plantar ulcers. Phys Ther. 1991;71(2):116–22.
48. Veves A, Murray HJ, Young MJ, Boulton AJM. The risk of foot ulceration in diabetic patients with high foot pressure: a prospective study. Diabetolgica. 1992;35:660–3.
49. Grant WP, Sullivan R, Sonenshine DE, et al. Electron microscopic investigation of the effects of diabetes mellitus on the Achilles tendon. J Foot Ankle Surg. 1997;36(4):272–8; discussion 330.
50. Rosenbloom AL, Silverstein JH, Lezotte DC, Riley WJ, Maclaren NK. Limited joint mobility in diabetes mellitus of childhood: natural history and relationship to growth impairment. J Pediatr. 1982;101(5):874–8.
51. Rosenbloom AL. Skeletal and joint manifestations of childhood diabetes. Pediatr Clin North Am. 1984; 31:569–89.
52. Birke JA, Franks D, Foto JG. First ray joint limitation, pressure, and ulceration of the first metatarsal head in diabetes mellitus. Foot Ankle. 1995;16(5):277–84.
53. Frykberg RG, Lavery LA, Pham H, Harvey C, Harkless L, Veves A. Role of neuropathy and high foot pressures in diabetic foot ulceration. Diabetes Care. 1998;21(10):1714–9 [In Process Citation].
54. Fernando DJS, Masson EA, Veves A, Boulton AJM. Relationship of limited joint mobility to abnormal foot pressures and diabetic foot ulceration. Diabetes Care. 1991;14:8–11.
55. Armstrong DG, Stacpoole-Shea S, Nguyen HC, Harkless LB. Lengthening of the Achilles tendon in diabetic patients who are at high risk for ulceration of the foot. J Bone Joint Surg Am. 1999;81A:535–8.
56. Birke J, Cornwall MA, Jackson M. Relationship between hallux limitus and ulceration of the great toe. J Orthop Sports Phys Ther. 1988;10:172–6.
57. Grayson ML, Balaugh K, Levin E, Karchmer AW. Probing to bone in infected pedal ulcers. A clinical sign of underlying osteomyelitis in diabetic patients. J Am Med Assoc. 1995;273(9):721–3.
58. Birke JA, Novick A, Patout CA, Coleman WC. Healing rates of plantar ulcers in leprosy and diabetes. Lepr Rev. 1992;63(4):365–74.
59. Reiber GE, Pecoraro RE, Koepsell TD. Risk factors for amputation in patients with diabetes mellitus: a case control study. Ann Intern Med. 1992;117(2): 97–105.
60. Wunderlich RP, Peters EJ, Armstrong DG, Lavery LA. Reliability of digital videometry and acetate tracing in measuring the surface area of cutaneous wounds. Diabetes Res Clin Pract. 2000;49(2–3): 87–92.
61. Oyibo SO, Jude EB, Tarawneh I, et al. A comparison of two diabetic foot ulcer classification systems. Diabetes. 2000;49 Suppl 1:A33.
62. Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation [see comments]. Diabetes Care. 1998; 21(5):855–9.
63. Armstrong DG, Peters EJ. Classification of wounds of the diabetic foot. Curr Diab Rep. 2001;1:233–8.
64. Meggitt B. Surgical management of the diabetic foot. Br J Hosp Med. 1976;16:227–332.
65. Wagner FW. The dysvascular foot: a system for diagnosis and treatment. Foot Ankle. 1981;2:64–122.
66. Smith RG. Validation of Wagner's classification: a literature review. Ostomy Wound Manage. 2003;49(1): 54–62.
67. Calhoun JH, Cantrell J, Cobos J, et al. Treatment of diabetic foot infections: Wagner classification, therapy, and outcome. Foot Ankle. 1988;9:101–6.
68. Van Acker K. The diabetic foot. A challenge for policymakers and health care professionals. Antwerp: Department of Medicine, University of Antwerp; 2000.
69. Forrest RD, Gamborg-Neilsen P. Wound assessment in clinical practice: a critical review of methods and their application. Acta Med Scand. 1984;687: 69–74.
70. Pecoraro RE, Reiber GE. Classification of wounds in diabetic amputees. Wounds. 1990;2(2):65–73.
71. Arlt B, Protze J. [Diabetic foot]. Langenbecks Arch Chir Suppl Kongressbd. 1997;114:528–32.
72. Knighton DR, Ciresi KF, Fiegel VD, Austin LL, Butler EL. Classification and treatment of chronic nonhealing wounds: successful treatment with autologous platelet-derived wound healing factors (PDWHF). Ann Surg. 1986;204:322–30.
73. Schaper NC. Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes Metab Res Rev. 2004;20 Suppl 1:S90–5.
74. Macfarlane RM, Jeffcoate WJ. Classification of diabetic foot ulcers: the S(AD) SAD system. Diabet Foot. 1999;2(4):123–31.
75. Jeffcoate WJ, Macfarlane RM, Fletcher EM. The description and classification of diabetic foot lesions. Diabet Med. 1993;10:676–9.
76. Lavery LA, Armstrong DG, Harkless LB. Classification of diabetic foot wounds. J Foot Ankle Surg. 1996;35(6):528–31.
77. Caputo GM. Infection: investigation and management. In: Boulton AJM, Connor H, Cavanagh PR, editors. The foot in diabetes. 2nd ed. Chichester: Wiley; 1994.
78. LoGerfo FW, Coffman JD. Vascular and microvascular disease of the foot in diabetes. N Engl J Med. 1984;311:1615–9.
79. Bacharach J, Rooke T, Osmundson P, Glovizzki P. Predictive value of trascutaneous oxygen pressure and amputation success by use of supine and elevation measurements. J Vasc Surg. 1992;15:558–63.
80. Carter S. Elective foot surgery in limbs with arterial disease. Clin Orthop. 1993;289:228–36.
81. Apelqvist J, Castenfors J, Larsson J. Prognostic value of ankle and toe blood pressure levels in

outcome of diabetic foot ulcers. Diabetes Care. 1989;12:373–8.
82. Orchard TJ, Strandness DE. Assessment of peripheral vascular disease in diabetes: report and recommendation of an international workshop. Diabetes Care. 1993;83(12):685–95.
83. Joseph WS. Handbook of Lower Extremity Infections. 1st ed. New York: Churchill Livingston; 1990.
84. Lavery LA, Armstrong DG, Quebedeaux TL, Walker SC. Puncture wounds: the frequency of normal laboratory values in the face of severe foot infections of the foot in diabetic and non-diabetic adults. Am J Med. 1996;101:521–5.
85. Molinar DM, Palumbo PH, Wilson WR, Ritts RE. Leukocyte chemotaxis in diabetic patients and their first degree relatives. Diabetes. 1976;25:880–9.
86. Bagdade JD, Root RK, Bulger RJ. Impaired leukocyte function in patients with poorly controlled diabetes. Diabetes. 1974;23:9–17.
87. Tan JS, Anderson JL, Watanakunakorn C, Phair JP. Neutrophil dysfunction in diabetes mellitus. J Lab Clin Med. 1975;85:26–33.
88. Armstrong DG, Lavery LA, Sariaya M, Ashry H. Leukocytosis is a poor indicator of acute osteomyelitis of the foot in diabetes mellitus. J Foot Ankle Surg. 1996;35(4):280–3.
89. Armstrong DG, Perales TA, Murff RT, Edelson GW, Welchon JG. Value of white blood cell count with differential in the acute diabetic foot infection. J Am Podiatr Med Assoc. 1996;86(5):224–7.
90. Armstrong DG, Lavery LA, Liswood PJ, Todd WF, Tredwell JA. Infrared dermal thermometry for the high-risk diabetic foot. Phys Ther. 1997;77(2):169–75; discussion 176–167.
91. Armstrong DG, Liswood PJ, Todd WF, William J. 1995 William J. Prevalence of mixed infections in the diabetic pedal wound. A retrospective review of 112 infections. J Am Podiatr Med Assoc. 1995;85(10):533–7.
92. Oyibo SO, Jude EB, Tarawneh I, Nguyen HC, Harkless LB, Boulton AJ. A comparison of two diabetic foot ulcer classification systems: the Wagner and the University of Texas wound classification systems. Diabetes Care. 2001;24(1):84–8.